Vertex Pharmaceuticals Logo

Email this page: News Release

Vertex Corrects and Provides Additional Data from Recent Interim Analysis of Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

For security reasons, registration is required before you can use this feature.
* Indicates required field